Trial · NCT04481412
Topical Cetirizine in Androgenetic Alopecia in Females
NCT04481412, Phase 2, Phase 3, Completed, Cairo University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Topical Cetirizine in Androgenetic Alopecia in Females. Trials, record NCT04481412. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04481412
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Cetirizine in Androgenetic Alopecia in Females
- NCT number
- NCT04481412
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 66 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Androgenetic Alopecia
- Interventions
- Topical cetirizine, Placebo, Topical minoxidil
- First posted
- 2020-07-22
- Last updated
- 2023-02-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change from baseline in number of terminal hairs and vellus hair | baseline, 12, 24 weeks | Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of terminal hairs, growing hair and vellus hair. |
| Primary | The change from baseline in hair shaft thickness | baseline, 12, 24 weeks | Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in hair shaft thickness. |
| Primary | The change from baseline in terminal and vellus hair density | baseline, 12, 24 weeks | Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of follicular openings. |
| Primary | The change in patient self-assessment from baseline | baseline, 6, 12, 18, 24 weeks | Patient self-assessment of hair growth will be determined by means of a set of predetermined 5 questions in Arabic, each of which asks the patient about a specific aspect of their hair compared with the start of the study. |
| Secondary | The change in hair growth from baseline using global photographic assessment | baseline, 12, 24 weeks | Standardized photographs of the scalp will be taken. 1. An expert panel of 3 blinded dermatologists will evaluate hair growth or loss from baseline by comparing baseline with follow-up photographs of each subject by means of a 7-point scale to answer the following question: "How would you subjectively rate the patient's hair growth at this time point compared to baseline?". The scale ranges from-3 ( greatly decreased) to +3 (greatly increased). Assessments will be made at the 12th and 24th week by comparing the global photographs taken at baseline with those taken at each visit. 2. Investigator assessment: Same as the expert panel assessment. |
| Secondary | Number of patients with adverse effects | 6, 12, 18, 24 weeks | Reports of adverse effects or local intolerance, if any, will be collected at every visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04481412
GET https://conductscience.org/api/trials/v1/NCT04481412/registered